TY  - JOUR
AU  - Wagemann, Olivia
AU  - Brendel, Matthias
AU  - Franzmeier, Nicolai
AU  - Nübling, Georg
AU  - Gnoerich, Johannes
AU  - Zaganjori, Mirlind
AU  - Prix, Catharina
AU  - Stockbauer, Anna
AU  - Wlasich, Elisabeth
AU  - Loosli, Sandra V
AU  - Sandkühler, Katja
AU  - Frontzkowski, Lukas
AU  - Höglinger, Günter
AU  - Levin, Johannes
TI  - Feasibility and potential diagnostic value of [18F]PI-2620 PET in patients with down syndrome and Alzheimer's disease: a case series.
JO  - Frontiers in neuroscience
VL  - 18
SN  - 1662-4548
CY  - Lausanne
PB  - Frontiers Research Foundation
M1  - DZNE-2025-00223
SP  - 1505999
PY  - 2025
AB  - Adults with Down Syndrome (DS) have a substantially increased risk for Alzheimer's disease (AD) due to the triplicated amyloid-precursor-protein gene on chromosome 21, resulting in amyloid and tau accumulation. However, tau PET assessments are not sufficiently implemented in DS-AD research or clinical work-up, and second-generation tau tracers such as [18F]PI-2620 have not been thoroughly characterized in adults with DS. We aim at illustrating feasibility and potential diagnostic value of tau PET imaging with [18F]PI-2620 for the diagnosis of DS-AD.Five adults with DS (40
KW  - 18F-PI-2620 (Other)
KW  - Alzheimer (Other)
KW  - case series (Other)
KW  - down syndrome (Other)
KW  - tau PET (Other)
KW  - trisomy 21 (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:39834700
C2  - pmc:PMC11744071
DO  - DOI:10.3389/fnins.2024.1505999
UR  - https://pub.dzne.de/record/276151
ER  -